Investigators have identified two promising new treatment options for men with recurrent prostate cancer — both of which helped patients live longer without their disease progressing than the current standard treatment. ‘If these treatments are approved by the Food and Drug Administration, our results will be practice changing,’ said Stephen Freedland, MD, associate director for Training and Education and the Warschaw, Robertson, Law Families Chair in Prostate Cancer at Cedars-Sinai, and lead author of the study. ‘In the study, both of these new options improved metastasis-free survival while preserving quality of life.’
